Travere Therapeutics, Inc. (TVTX) AI Stock Analysis

Travere Therapeutics, Inc. is a biopharmaceutical company founded in 2008 and based in San Diego, California. It focuses on discovering, developing, and commercializing therapies for rare diseases and underserved patient groups. Its commercial portfolio features Chenodal for radiolucent gallbladder stones, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Thiola and Thiola EC for homozygous cystinuria. Travere's development pipeline includes Sparsentan, which is in Phase III trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, as well as TVT-058, an enzyme replacement therapy in Phase I/II trials for classical homocystinuria.

Travere's revenue expanded at a 5-year CAGR of 19.9% from FY2020 to FY2025. Following declines in FY2021 and FY2022, revenue rose 32.7% in FY2023 to $145.2M, 60.5% in FY2024 to $233.2M, and 110.5% in FY2025 to $490.7M. Gross margins remained high across the period, standing at 97.9% in FY2025. Operating margin improved from -138.9% in FY2024 to -12.8% in FY2025, while net income narrowed to -$25.5M. For the latest quarter ended June 30, 2026, quarterly revenue growth was 48.2% year-over-year, bringing trailing twelve-month revenue to $591.3M with an operating margin of 2.3% and EPS of -$0.74.

As of June 30, 2026, Travere held $489.2M in cash and short-term investments against total debt of $616.9M, resulting in net debt of $127.7M. The company reported total assets of $799.4M and shareholders' equity of $24.5M, giving a debt-to-equity ratio of 25.16 and a current ratio of 4.05. Operating cash flow improved to $37.8M in FY2025, while free cash flow stood at -$20.4M after capital expenditures of $58.2M. Dilution occurred over the long term, with share count increasing 51.7% over 5 years.

Travere holds a market capitalization of $4.61B and an enterprise value of $5.77B. The stock trades at a forward P/E of 39.8x and a price-to-sales ratio of 7.9x, both higher than the median of its US-listed Healthcare peers at 17.3x and 4.1x, respectively. Its EV/EBITDA multiple is 998.0x compared to the peer median of 12.0x. Over the past year, TVTX gained 80.3%, outperforming the S&P 500 benchmark return of 16.8%, and delivered a 5-year return of 102.4% against the benchmark's 83.0%.

Wall Street coverage includes 12 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $75.21, representing an upside of 51.6% from the last close of $49.60. For the fiscal year ending December 31, 2026, analysts estimate revenue of $724.6M and EPS of $1.69. For the following fiscal year, 8 analysts project revenue of $1.08B and EPS of $5.64. Travere has beaten EPS estimates in 3 of the last 4 quarters, with its next earnings report scheduled for October 29, 2026.

This page is an AI-written research summary of Travere Therapeutics, Inc. (TVTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TVTX income statement, TVTX balance sheet, TVTX key metrics, TVTX analyst forecast, TVTX chart. See the TVTX stock overview for the latest quote and news.